Altimmune ALT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $41K+105% | $20K-95.3% | $426K+726% | -$68K-102% | ||
| $66.43M-19.2% | $82.23M+25.0% | $65.8M-6.7% | $70.54M-5.4% | ||
| $28.1M+34.0% | $20.97M+15.6% | $18.14M+5.9% | $17.13M+11.2% | ||
| $94.53M-8.4% | $103.19M+7.1% | $96.36M+9.9% | $87.67M-13.5% | ||
| -$94.49M+8.4% | -$103.17M-7.6% | -$95.93M-9.3% | -$87.74M+9.5% | ||
| -230,461%+285,399pp | -515,860%-493,341pp | -22,518.5%-151,548pp | 129,029.4%+131,227pp | ||
| $1.64M+18,078% | $9K-74.3% | $35K— | —— | ||
| $5.72M-29.6% | $8.11M+8.4% | $7.48M+164% | $2.83M— | ||
| -$88.77M+6.6% | -$95.06M— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$88.09M+7.3% | -$95.06M-7.5% | -$88.45M-4.4% | -$84.71M+12.7% | ||
| -214,861%+260,434pp | -475,295%-454,533pp | -20,762.2%-145,340pp | 124,577.9%+126,780pp | ||
| -$1.00+25.4% | -$1.34+19.8% | -$1.67+6.2% | -$1.78+24.3% | ||
| -$94.38M+8.3% | -$102.93M-5.9% | -$97.23M-10.6% | -$87.95M+8.7% | ||
| -230,187.8%+284,482pp | -514,670%-491,847pp | -22,823.5%-152,154pp | 129,330.9%+131,516pp | ||
| -$94.49M+8.4% | -$103.17M-7.6% | -$95.93M-9.3% | -$87.74M+9.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Altimmune's revenue?
- Altimmune (ALT) generated $41.0K in revenue over the trailing twelve months, up 105.0% year over year.
- Is Altimmune profitable?
- Altimmune is not currently profitable: it reported a net loss of $91.1M over the trailing twelve months, a -214861.0% net margin.
- What is Altimmune's earnings per share?
- Altimmune's diluted EPS over the trailing twelve months is $-0.92.
- Where does Altimmune's income statement data come from?
- Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
